ÌÇÐÄvlog´«Ã½

Chemiluminescence Immunoassay (CLIA) Market Analysis

The chemiluminescence immunoassay market is expected to grow at a CAGR of 6.6% during the forecast period (2022-2027).

The Covid-19 pandemic is anticipated to have a considerable impact on the studied market. During the initial phase of the pandemic due to strict lockdown and shut down the laboratories, diagnostic centers, and research units were closed, so there was a decline in the number of assays performed, which hampered the market growth. However, soon after the situation stabilized population across the globe returned to work and it was critical to develop tests that reliably detect SARS-CoV-2-specific antibodies. Hence researchers started procuring different assays for the detection of the virus. For instance, research conducted by a group of scientists in the United States presented their results from a multiplex serology test for assessing the antibody responses to COVID-19. And their research was published in February 2021 titled 'A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients'. As per the research article, the chemiluminescent immunoassay (CLIA) can demonstrate high clinical sensitivity and specificity and can reliably be used to diagnose infection by SARS-CoV-2. Such research provided information on the efficiency of the CLIA tests, which is expected to impact the demand for CLIA methods. Therefore, the pandemic is expected to have a significant impact on the market studied.

The chemiluminescence immunoassay (CLIA) has been applied in different fields including environmental monitoring, liquid chromatography, clinical diagnosis, food safety, pharmaceutical analysis, immuno-, and gene probe assays, as a promising approach for selective, sensitive, rapid, and simple analysis. The article 'Detection of Circulating varicella-zoster virus (VZV)-Glycoprotein E (gE)-Specific Antibodies by Chemiluminescent Immunoassay (CLIA) for Varicella-Zoster Diagnosis' published in January 2022 stated that the CLIA approach-based detection kit for diagnosing VZV-gE-specific IgA (immunoglobulin-A), IgG (immunoglobulin-G), and IgM (immunoglobulin-M) is simple, and suitable for high-throughput routine analysis situations, also provides enhanced specificity compared to ELISA (enzyme-linked immunoassay). Thus, such research providing positive results of CLIA methods is anticipated to drive market growth.

Furthermore, chronic diseases such as cancer, cardiovascular diseases, diabetes, Alzheimer's diseases, and respiratory disorders are increasing day by day globally. And the detection of the mechanism behind the disease is crucial to further accelerate the drug development and treatment process. Thus, scientists are recently adopting the CLIA method for such research purposes. The research article 'Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer's Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma' published in May 2022 stated that the researchers established a direct standard CLIA curve under optimized conditions for total tau detection in Alzheimer's patients and the results showed that CLIA provided fairly repeatability and reliability compared to other detection technologies. Such reliability of the detection method is creating demand for the use of the methods, thereby contributing to the growth of the market studied.

Therefore, owing to the aforesaid factors the studied market is predicted to witness growth over the forecast period. However, the lack of skilled professionals to handle these methods is anticipated to hinder market growth over the forecast period.

Chemiluminescence Immunoassay (CLIA) Market Trends

This section covers the major market trends shaping the Chemiluminescence Immunoassay (CLIA) Market according to our research experts:

Oncology Segment is Expected to Hold the Largest Market Share

Chemiluminescence Immunoassay (CLIA) Industry Segmentation

As per the scope of the report, chemiluminescence (CL) is described as the discharge of electromagnetic radiation owing to the production of light by a chemical reaction. Chemiluminescence immunoassay (CLIA) is an assay incorporating the technique of chemiluminescence with immunochemical reactions. The chemiluminescence immunoassay (CLIA) market is segmented by Product Type (Analyzers, Reagents, and Consumables), Application (Oncology, Autoimmune Disorder, Infectious Disease, Cardiovascular Disease, Endocrine Disorders and Others), End-User (Pharmaceutical and Biotechnology Companies, Hospital and Clinical Laboratories and Others), and Geography (North America, Europe, Asia Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.